Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab.

作者
Stefano Cascinu,Alberto Zaniboni,Sara Lonardi,Gerardo Rosati,Guglielmo Nasti,Monica Giordano,Domenico Corsi,Francesco Ferraù,Rosario V. Iaffaioli,Paolo Marchetti,Massimo Aglietta,Domenico Bilancia,Monica Ronzoni,Irene Floriani,Roberto Labianca
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:34 (4_suppl): 632-632 被引量:1
标识
DOI:10.1200/jco.2016.34.4_suppl.632
摘要

632 Background: FOLFOX/FOLFIRI are effective as first-line treatment but FOLFOX might be more effective in second line. The optimal first-line in RAS wild type mCRC is still unclear even after 2 trials comparing chemotherapy with bevacizumab or cetuximab. While bevacizumab seems to loose efficacy across treatment lines, cetuximab has a similar activity across all treatment lines. It might be a better choice for the third-line in the view of an optimal sequence strategy. We designed a phase III randomised trial to compare two different treatment sequences of cetuximab and FOLFOX in mCRC patients refractory to FOLFIRI/bevacizumab first-line. Methods: Pts were randomized to receive Irinotecan/Cetuximab as 2 nd line followed by FOLFOX-4 as 3 rd line (Arm A) or the inverse sequence. Primary endpoint was progression free survival (PFS); secondary endpoints were overall survival and toxicity. 101 events were required in order to detect an hazard ratio of 0.57, translating in an increase of median PFS from 4 to 7 months (two-sided type I error 5%, power 80%). Results: 110 mCC pts were enrolled in this trial: 64 pts were males and 46 females with a mean age of 61 years. Efficacy results are reported in the table. Treatment was well tolerated with a low number of serious adverse reactions (2 in each treatment arm). Conclusions: Cetuximab is less effective immediately after bevacizumab. This is in accordance with data suggesting that EGFR inhibition is not active after VEGF blockade. The sequence of biological agents seems to be more relevant than the first-line choice. In RAS wild type patients progressing after a first line bevacizumab based therapy cetuximab should be given as first line or third line. Clinical trial information: NCT01030042. [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
情怀的应助被科研通管家采纳,获得10
刚刚
Owen的应助被科研通管家采纳,获得10
刚刚
刚刚
DELON完成签到,获得积分10
刚刚
秋风的应助被科研通管家采纳,获得20
1秒前
1秒前
脑洞疼的应助被wly采纳,获得10
1秒前
田様的应助被心事全在脸上采纳,获得10
2秒前
自由凌丝完成签到,获得积分10
2秒前
2秒前
Mecury完成签到,获得积分10
2秒前
skycool发布了新的文献求助10
2秒前
yooookiiki完成签到 ,获得积分10
2秒前
大道希言发布了新的文献求助10
3秒前
Easton丶完成签到,获得积分10
3秒前
3秒前
打打的应助被bill采纳,获得10
3秒前
4秒前
勤奋小懒虫完成签到,获得积分10
4秒前
123完成签到,获得积分10
5秒前
5秒前
fantasy的应助被wztin采纳,获得10
6秒前
香蕉松松饼完成签到 ,获得积分10
6秒前
结实的寒烟完成签到,获得积分10
7秒前
爆米花的应助被来一杯忌廉采纳,获得30
7秒前
txfxh完成签到,获得积分20
7秒前
8秒前
传奇3的应助被ccm采纳,获得10
8秒前
丰富的荧完成签到,获得积分10
8秒前
莫天枫完成签到,获得积分10
8秒前
8秒前
GIK尘完成签到,获得积分20
8秒前
山石梦沧海完成签到,获得积分10
9秒前
123发布了新的文献求助10
9秒前
9秒前
hihihihi发布了新的文献求助10
9秒前
乐乐的应助被小高子采纳,获得10
9秒前
Sato完成签到,获得积分10
10秒前
打打的应助被小杨肖恩采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175534
求助须知:如何正确求助?哪些是违规求助? 9567220
关于积分的说明 21791292
捐赠科研通 7770111
什么是DOI,文献DOI怎么找? 3431868
关于科研通互助平台的介绍 2556244
邀请新用户注册赠送积分活动 2477299